In prehypertrophic Fabry disease, low myocardial T1 values, reflecting sphingolipid storage, are associated with early structural and ECG changes. The correlations between T1 values and functional parameters have not been explored. Furthermore, the potential prognostic role of T1 in predicting disease worsening is still unknown.
F
abry disease (FD) (OMIM 301500) is a rare X-linked lysosomal disorder, caused by deficiency or lack of the enzyme α-galactosidase A (GLA gene). Reduced enzyme activity results in progressive accumulation of the natural substrate globotriaosylceramide in tissues, leading to a systemic disease mainly affecting cardiovascular, renal, and nervous systems.
1 Heart involvement is characterized by left ventricular hypertrophy (LVH), myocardial scarring, bradyarrhythmias or tachyarrhythmias, and heart failure 2 and represents the main cause of death in these patients. 3 Since 2001, specific therapies (enzyme replacement therapy [ERT] first and pharmacological chaperone migalastat more recently) are available to reverse, stabilize, or slow down disease course. [4] [5] [6] Cardiac magnetic resonance (CMR) plays a pivotal role in staging cardiac damage. Beyond its accuracy in left ventricular (LV) mass quantification, CMR allows discrimination of borderline cases of LVH 7 and offers the unique possibility of noninvasive tissue characterization. In the last years, tissue characterization by CMR has progressed from late gadolinium enhancement (LGE), allowing detection of myocardial scarring in the advanced phase of cardiac damage, 8 to native (noncontrast) T1 mapping, 9 reflecting myocardial disease involving both myocytes and interstitium. Native T1 is known to be higher in the presence of myocardial fibrosis, edema, and amyloid and lower in iron overload and fat infiltration. [10] [11] [12] Low native T1 values have been reported not only in FD patients with LVH but also in a subgroup (40%-60%) of patients without overt cardiac involvement. [13] [14] [15] In prehypertrophic FD, a correlation between increasing LV mass and reduction of T1 has been recently described in both sexes. 16 Moreover, in FD patients with no LVH, the presence of low T1 values has been associated with a higher frequency of electrocardiographic abnormalities and higher LV mass, maximum LVWT, and ejection fraction. Beyond these early structural and ECG changes, the functional implications of low T1 values in terms of systo-diastolic function and cardiac arrhythmias are still unclear. Furthermore, it remains unclear whether low T1 in prehypertrophic FD can predict disease worsening, thus representing an additional indication for specific therapy.
We aimed to investigate, in a population of prehypertrophic FD patients, (1) the functional correlations of low T1 values, in terms of systo-diastolic function, exercise capacity, and cardiac arrhythmias; and (2) the prognostic value of myocardial T1 in predicting disease worsening.
METHODS
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Study Population
Among 65 consecutive patients with diagnosis of FD referred for CMR at Multimodality Cardiac Imaging Unit of Policlinico San Donato (Milan, Italy) from December 2015 to June 2017, 46 patients without LVH from 26 different families were prospectively recruited. Two female patients were excluded because their genetic defect had been previously classified as polymorphism of GLA gene (c.375A>G, p.S126G). 17 Thus, study population included 44 patients with genetically confirmed FD and with no LVH. The presence of LVH was defined as an increased LVWT ≥13 mm in ≥1 LV myocardial segments, according to the current guidelines on diagnosis of hypertrophic cardiomyopathy in first-degree relatives. 18 Baseline evaluation included ECG, echocardiographic examination, cardiopulmonary test, contrast-enhanced CMR, and calculation of Mainz Severity Score Index (MSSI). 19 After a median follow-up of 12.7 months (11.9-13.3 months) according to the current recommendations, 20 patients underwent clinical revaluation including ECG, 2D echocardiography, calculation of MSSI, and Fabry Stabilization Index (FASTEX). 21 MSSI and FASTEX are 2 disease severity scoring systems; the former provides an index of disease severity at a single time point, that is, a snapshot of the clinical status of the individual patient, whereas the second one has been recently developed to specifically evaluate clinical stability or progression of FD. Clinical worsening at follow-up was defined as FASTEX >20%.
The study received approval from the local research ethics committee, and all participants provided written informed consent.
CMR Study
CMR was performed on a 1.5-T magnet (MAGNETOM Aera; Siemens Healthcare, Erlangen, Germany). LV volumes, mass, and ejection fraction were calculated from steady-state free precession cine images using a thresholding method by Medis software (Qmass, MR version 6.2.1; Medis Medical Imaging Systems, Leiden, The Netherlands). For each myocardial segment, according to the American Heart Association 16 segments model, maximum end-diastolic wall thickness was
CLINICAL PERSPECTIVE
Clinical management of Fabry patients with low disease burden, mainly heterozygous females with no clear evidence of disease manifestations, represents a major challenge in the field of Fabry disease. Cardiac magnetic resonance with T1 mapping can provide additional information beyond left ventricular hypertrophy that can be useful in the routine decision-making. In fact, in prehypertrophic Fabry disease, low myocardial T1 values identify patients with early ECG, morphological cardiac changes, and higher disease burden. These patients have higher risk of clinical worsening compared with patients with normal T1 values, thus suggesting a closer follow-up and timely adoption of specific therapeutic strategies. measured in cine images. Patient-specific shimming was performed, and a shim box was placed tightly over the heart as recommended. 9 T1 measurement was performed using a Shortened Modified Looked Locker inversion recovery sequence (Work-in-Progress No. 780B VD13A-SP4) before and 15 minutes after 0.1 mmol/kg of contrast (Gadovist; Bayer Schering Pharma, Berlin, Germany). Shortened Modified Looked Locker inversion recovery sequences were acquired in basal/mid-ventricular short axis and in horizontal/vertical long axis. Optimal gating and breath-holding were ensured, and raw images and R 2 maps were examined for potential image artifacts during scanning, to allow an immediate repeat of suboptimal measurement. 9 Inline generated T1 maps were analyzed using Argus software (Siemens Healthineers, Erlangen, Germany). T1 values were measured in the midseptum, anterior, inferior, and lateral LV walls. For each LV wall, a region of interest was drawn both from mid-ventricular short axis and horizontal or vertical long axis, taking care to clearly avoid the blood-myocardial boundary, and the mean T1 value was calculated. For T2 mapping, T2 prepared gradient-echo pulse sequences (Work-in-Progress No. 780B VD13A-SP4) were acquired before contrast medium administration in basal, mid-ventricular, and apical short axis. T2 values were systematically measured in midseptum and LV inferolateral wall, taking care to clearly avoid the blood-myocardial boundary. Two expert operators (A.C. and S.P., Level 3 ESC Certification) performed T1 and T2 mapping analyses: A.C. analyzed the same T1 mapping sequences twice for intraobserver reproducibility, S.P. reanalyzed the same images making interobserver data available. The T1 Mapping and ECV Standardization Program phantom was scanned as part of the T1 Mapping and ECV Standardization Program Multicenter Study. 22 The coefficient of variation for repeated measurements varied from 0.870 to 3.294 at a mean temperature of 21°C. Two-dimensional Gradient Echo Inversion Recovery LGE images were obtained 8 to 10 minutes after contrast.
Myocardial feature tracking technique was also applied on 3 long-axis (vertical, horizontal long axis, and 3 chambers) cine images using Medis software (version 2.1.12.2.; Qstrain, Medis Medical Imaging Systems, Leiden, the Netherlands). After manual drawing of LV epicardial and endocardial border, the quantitative assessment of myocardial deformation (systolic global longitudinal strain) was obtained. 23 Study population was compared with a sex-matched, age-matched, and body surface area-matched cohorts of 22 healthy volunteers.
ECG, Echocardiographic Examination, and Cardiopulmonary Test
ECG analysis included assessment of cardiac rhythm, PR interval, QRS interval, Sokolow-Lyon Index (SLI), and presence/ absence of repolarization abnormalities (ST-segment depression, flat/negative T waves). Echocardiographic evaluation was performed using Philips Epiq 9. A routine study was performed, according to standard protocols of the European Society of Cardiology, including evaluation of diastolic function with conventional Doppler-based measurements (transmitral peak early filling (E) to late diastolic filling (A) velocities ratio (E/A), peak early filling (E) to early diastolic mitral annular tissue (e') velocities ratio (E/e'), left atrial [LA] volume index).
All subjects underwent a symptom-limited Cardio-Pulmonary Exercise Test. 24 Individualized ramp protocols were designed to obtain a standard of exercise, using a ramp steep of 12 to 20 W/min. Ventilatory expired gas analysis was performed using a metabolic cart (Vmax; Sensormedics, Yorba Linda, CA).
FASTEX Calculation
FASTEX was calculated by the online application (www.fastex. online) comparing baseline and last follow-up evaluation as previously described. 21 Median interval between baseline and last evaluation was 12.7 months (11.9-13.3 months).
Statistical Analysis
Patients' characteristics were summarized by mean, SD, median, first, and third quartiles for continuous and counts and percent for categorical variables.
Normality assumption was checked by the Shapiro-Wilk test. Categorical variables were compared by the χ 2 test or Fisher exact test as appropriate, whereas continuous parameters were analyzed using the 2-sample Wilcoxon test for nonnormally distributed data (Kolmogorov-Smirnov test).
Correlation between native myocardial T1 measurements and age, MSSI, main ECG, echocardiographic, and CMR parameters were estimated by the Pearson correlation coefficient.
The intra-and interobserver agreement of T1 values was estimated by the intraclass correlation coefficient and the coefficient of variation.
Univariate logistic regression was used to explore the association between FASTEX (categorized according to a 20% threshold) and putative prognostic factors.
Nonparametric paired tests were used to evaluate the difference between baseline and 1-year follow-up in ECG and echocardiographic parameters.
All tests were 2-sided and considered statistically significant at the 0.05 level. All analyses were done using SAS 9.4 (Cary, NC).
RESULTS

Study Population
Baseline characteristics of the study population are shown in Table 1 .
Mean age of patient population was 35.7±14.5 years, with a prevalence of females (68.2%). The median MSSI was 12.0 (9.0-21.5) with 12 patients (27.3%) presenting an MSSI >20.
All patients had a genetically confirmed diagnosis of FD and the majority of them (68.2%) exhibited a mutation previously associated with the classical form of FD; 23 (52.3%) patients had a missense mutation, 13 (29.5%) patients had deletions, 7 (15.9%) patients had truncating mutations, and 1 (2.3%) patient had a splice site mutations.
Eighteen patients (40.9%) were treated with ERT at the time of this study, 13 (72.2%) with agalsidase alfa, 5 (27.8%) with agalsidase beta at currently approved dosages. Median ERT duration was 120.0 months (23.0-175.0 months).
Healthy volunteers (age, sex, and body surface area matched, same scanner/setup/sequence) were used to define the normal range of native myocardial T1 and T2 values and systolic strain parameters. Mean T1 values were 971±22 ms in the total population; 959±20 ms in the male subgroup; and 984±18 ms in the female subgroup. These reference values were similar to those reported in the previous studies with the same scanner/sequence. 13 Mean T2 values were 39±2 ms in the total population; and 39±2 ms both in the male and female subgroup. Reference ranges for global longitudinal strain were (mean, SD) −21.0±4.6%, similar to previous works. 25 
Baseline Assessment
Normal T1 Versus Low T1 FD Patients Native myocardial T1 values were similar in midseptum, anterior, inferior, and lateral LV walls (intraclass correlation coefficient, 0.97; CI, 0.94-0.98); thus, septal T1 was considered for each patient. T1 value in the FD global cohort was lower than that in the healthy volunteers (906 versus 971 ms; P=0.001). On the basis of reference T1 values in healthy volunteers, FD patients were divided into 2 groups according to the presence of normal or low (>2 SD below mean of healthy controls) myocardial T1 values (normal T1, n=18, 40.9%; Low T1, n=26, 59.1%; ; % of predicted value, 57.5±14.6%), but no association 
P=0.26).
Two female patients had a history of cardiac arrhythmias, one with previous catheter ablation of atrial fibrillation and the other with nocturnal phase of 2:1 atrioventricular block. In the second patient, electrophysiological study was performed and normal conduction parameters and sinus node recovery time were detected. Both patients had low T1 values, LGE in inferolateral wall, and classical mutations. 
Correlations of T1 Values in FD Cohort
Characteristics of FD Patients According to Genotype and Previous ERT
There was no significant difference among patients with classical versus nonclassical mutation in terms of age (36.7 versus 33.5 years; P=0.52); a slight higher prevalence of females in the group of nonclassical mutations was observed (60.0% versus 40.0%; P=0.09). FD patients with classical mutations had higher score of disease severity compared with patients with nonclassical mutations (MSSI, 17.4 versus 9.7; P=0.001), higher LV The 2 patients carriers of a GLA gene polymorphism and excluded from study population were sisters (females, 53 and 56 years old). They had normal ECG and echocardiographic parameters and normal T1 values (986 and 987 ms).
Patients assuming ERT did not show significant difference in T1 values compared with naive patients, neither among females (T1 in ERT+, 927±67; T1 in ERT−, 930±55; P=0.79) or males (T1 in ERT+, 857±68; T1 in ERT−, 860±68; P=0.94).
Reproducibility
Native myocardial T1 measurements with Shortened Modified Looked Locker inversion recovery sequences were highly reproducible. Intraobserver and interobserver reproducibility were similarly very good, showing an intraclass correlation coefficient of 0.99 and a coefficient of variation of 7.58% for intraobserver reproducibility and 7.88% interobserver reproducibility.
Follow-Up Evaluation
FD patients underwent clinical evaluation after a median follow-up of 12.7 months (11.9-13.3 months) as recommended. 21 Only 1 hospitalization was reported in a young female patient for psychiatric problems, apparently not related to FD. No major cardiovascular events occurred during follow-up. Four female patients started specific therapy for FD (1 with agalsidase alfa, 3 with Migalastat), 2 of them for renal involvement and the other 2 for detection of low myocardial T1 values and ECG abnormalities at baseline assessment, associated with signs of systemic involvement (cornea verticillata, hypohidrosis) and family history of Fabry cardiomyopathy.
Clinical worsening related to FD, defined as FASTEX >20%, was observed in 5 patients (mean age, 40.0±12.4; 2 females; Table 3 ): 4 patients showed evolution of renal involvement (increasing proteinuria or decreasing estimated glomerular filtration rate) with stable cardiac condition. The other patient (female, 54 years old) developed peripheral pain worsening and atrioventricular block progression from nocturnal 2:1 atrioventricular block to diurnal 2:1 and 3:1 atrioventricular block associated with lightheadedness. Due to the worsening of cardiac conduction disease, this patient repeated CMR after 1-year follow-up: LV mass, LVWT, and septal T1 remained stable, whereas a slight increase in T1 values in inferolateral wall together with the extension of LGE-positive area was observed (Figure 3) . This patient refused both pacemaker implantation and specific therapy for FD. All 5 patients who experienced clinical worsening had low T1 values at baseline evaluation (Table 4) . Three of these patients were on ERT: 2 young males (35 and 38 years old) since 2001 and 1 female (50 years old) since baseline evaluation. The other 2 patients (including the female patient with atrioventricular block) refused specific therapy for FD.
Excluding the patient with progression of atrioventricular block, no significant change of ECG parameters was observed in the overall population.
No significant change in echocardiographic parameters was observed at follow-up apart from a slight increase in LA volume (24.0 versus 25.0 mL/m 2 ; P=0.03) in the overall population (Table C in the Data  Supplement) .
At logistic regression analysis, higher values of LVWT (odds ratio, 2.61; CI, 1.04-6.57; P=0.04), LA volume (odds ratio, 1.24; CI, 1.02-1.51; P=0.03), and reduced T1 values (odds ratio, 0.98; CI, 0.96-0.99; P=0.03) at baseline were risk factors for clinical worsening (Table 4) . Among patients presenting a significant clinical progression of FD (FASTEX >20%), 100% showed low baseline T1 versus only 53% of patients with no clinical progression (P=0.07).
DISCUSSION
FD is a chronic lysosomal storage disease leading to a storage hypertrophic cardiomyopathy. Early diagnosis of organ damage and early treatment are essential for optimal management, as ERT has been demonstrated effective in preventing major complications and in slowing disease progression mostly when administered early in the disease course. 26 Timely detection of cardiac involvement and starting of specific therapies are therefore crucial in particular in subjects with low disease burden.
In the present study, we confirmed that in prehypertrophic stage of Fabry cardiomyopathy, low T1 values were associated with early morphological and electrocardiographic changes. We also observed a significant correlation between native T1 values and MSSI, demonstrating that lowering of T1 values parallels not only the progressive thickening of cardiac walls but also the systemic clinical progression of the disease. Moreover, together with LVWT and LA volume, low T1 was a risk factor for clinical worsening at 12-month follow-up, thus representing a new prognostic marker and an important parameter to consider in the management of prehypertrophic patients.
Morphological, Functional, and Genetic Correlates of T1 Values
We documented a significant inverse correlation between T1 values and LV mass/LVWT together with a significantly higher prevalence of ECG abnormalities in patients with low T1 values, in line with recent findings by Nordin et al. 16 Interestingly, although overall T1 was significantly lower in males than in females, these correlations were significant irrespectively of age and sex, thus confirming the consistency of our observations and the accuracy of native T1 in tracking the progression of early stages of myocardial disease in both sexes. The presence of classical mutations was associated with lower T1 values, suggesting a more prominent myocardial involvement due to more severe enzymatic deficiency and more extensive myocardial glycolipid storage. Conversely, the 2 patients with polymorphism of GLA gene excluded from final analysis of data showed no evidence of cardiac involvement including normal T1 values, thus further supporting the nonpathogenic role of this polymorphism and suggesting a potential role of T1 mapping in evaluating the myocardial effects of unknown variants of GLA gene. On the other hand, we did not observe significant differences in systo-diastolic parameters and exercise tolerance comparing patients with normal and low T1. This is in line with the disease developmental model recently proposed by the London group, suggesting that systodiastolic function and cardiac arrhythmias occur in the presence of LVH and myocardial inflammation/fibrosis in more advanced stages of Fabry cardiomyopathy. 27, 28 Indeed, in our population, only 2 patients with low T1 values and LGE presented a history of cardiac arrhythmias. The study of myocardial edema with T2 mapping sequences showed a slight increase of T2 values in LGE-positive area only in 1 patient, consistently with the very early stage of cardiac involvement in our population. With regard to ERT, given the small and heterogeneous population with a very early cardiac disease, we found no significant difference comparing naive patients and patients assuming ERT, or between different ERT regimens nor sexes.
Native T1 and Clinical Progression
All 5 patients presenting a significant clinical progression of FD (FASTEX >20%) showed low baseline T1 values. Although the majority of these patients showed worsening of renal involvement, 1 female patient experienced a significant progression of conduction disturbances with an indication to pacemaker implantation. Follow-up CMR in this case showed a slight increase in T1 values in inferolateral wall together with an extension of LGE area despite a stability of LVH, thus suggesting a good accuracy of CMR in detecting progression of Fabry cardiomyopathy. Interestingly, lower T1 values at baseline, together with higher LVWT and LA volume, were independently associated with clinical worsening at follow-up. Accordingly, although not statistically significant due to small numbers, the prevalence of low T1 was higher among patients with clinical progression compared with stable patients.
To the best of our knowledge, this is the first evidence that low myocardial T1 values are associated with FD progression. This observation adds a new potential decision-making factor in the clinical management of FD patients with low disease burden. There is growing evidence that the therapeutic approach to FD must be optimized in terms of timing and dosage of specific therapies and in terms of additional therapies, according to genotype, metabolic profile, and rate of disease progression. 21 This is particularly important when dealing with heterozygous FD female patients with no clear evidence of disease manifestations in other target organs and tissues, whose clinical onset is often delayed over time. The possibility to characterize by CMR the T1 status of Fabry patients with therapeutic and prognostic implications should prompt the widespread application of this imaging modality in the field of FD, to have an additional tool in the complex clinical management of these patients. Regardless of the presence of LVH, functional and rhythm abnormalities, the evidence of low myocardial T1 values identifies FD patients with high disease burden and high risk of clinical worsening, requiring close follow-up and the timely adoption of appropriate therapeutic strategies.
Limitations of the Study
Study population was mainly composed by heterozygous female patients. By focusing on patients without LVH, we automatically enrolled many subjects with mild disease severity and most females, given the X-linked pattern of inheritance of the disease. CMR findings were not compared with myocardial histology, so we could not correlate early T1 reduction with the effective degree of glycolipid storage and myocyte hypertrophy. We did not measure extracellular volume in our population, as several previous studies showed extracellular volume within normal range in FD patients.
Conclusions
In conclusion, in prehypertrophic FD, low T1 values correlate with early electrocardiographic and morphological cardiac changes and worsening of systemic disease clinical manifestations.
The presence of low T1 values is a risk factor for disease worsening at 12-month follow-up, thus representing a potential new marker in prognostic stratification and therapeutic approach. 
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